Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab De-escalation in Pediatric Atopic Dermatitis
NCT06116526Phase 4Terminated
- Sponsor
- Johns Hopkins University
- Start
- Apr 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Johns Hopkins University. Started Apr 2024; status: terminated.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06116526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116526.